Predictors of lung cancer among former asbestos-exposed workers

Świątkowska, Beata; Szubert, Zuzanna; Sobala, Wojciech; Szeszenia-Da̧browska, Neonila

doi:10.1016/j.lungcan.2015.06.013

Cited by 18 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lung cancer is the most common cancer and the leading cause of cancer-related mortality in males worldwide with roughly 1.8 million new cases diagnosed in 2012 (13% of all cancers) (1). Risk factors including exposure to environmental and occupational carcinogens have been associated with an increased incidence of lung cancer (2). It is well established that lung cancer is a clinically and pathologically heterogeneous disease and has been classified into two main histological types non-small cell lung cancer (NSCLC) including squamous cell carcinoma, adenocarcinoma and large cell carcinoma and small cell lung cancer based on the origin of epithelial cell precursors (3).…”

Section: Introductionmentioning

confidence: 99%

Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis

Hu¹,

Li³

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Puerarin, an isoflavone isolated from Kudzu roots, has been demonstrated to have beneficial effect on cardiovascular and cerebral vascular diseases. Recently research has revealed that puerarin exerts an anticancer role in many different types of cancer. The aim of the present study was to investigate the antitumor effects of puerarin on non-small cell lung cancer (NSCLC). Treatment of puerarin significantly inhibited the growth of NSCLC cell lines as determined by CCK-8 kit in vitro. Flow cytometry results indicated that puerarin treatments promoted NSCLC cell apoptosis. This result was further confirmed by western blot analysis of expression levels of proteins involved in the mitochondrial-mediated apoptosis pathway. Moreover, puerarin slightly induced cell autophagy through the PI3K/Akt and MAPK/Erk1/2 signaling pathways. In addition, a tumor xenograft model was established using nude mice, and the inhibitory effects on tumor growth by puerarin treatment were also detected. Taken together, these findings demonstrated that puerarin has anticancer activities and puerarin is a potential therapeutic agent for lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis

Hu¹,

Li³

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…It is well established that LC is a clinically and pathologically heterogeneous disease and has been categorized into two main histological types non-small cell lung cancer (NSCLC) including squamous cell carcinoma, adenocarcinoma as well as large cell carcinoma and small cell lung cancer based on the origin of epithelial-cell precursors [ 2 ]. Risk factors including exposure to environmental and occupational carcinogens, have been associated with an increased incidence of LC [ 3 ]. The overall survival rate of LC patients is remarkably improved if diagnosis is confirmed at early stages, but limited access to effective screening with X-ray or computed tomography remains a problem [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer

et al. 2017

View full text Add to dashboard Cite

Lung cancer (LC) remains associated with significant mortality worldwide. The lack of reliable noninvasive biomarkers and targeted therapies contributes to poor survival rate. Herein, we initially took advantage of the public microarray data from Oncomine database to filter messenger RNAs (mRNAs) as potential biomarkers. Subsequently, clinical validation was applied to identify candidate noninvasive biomarkers in plasma from patients with LC. Through comprehensive analysis of transcriptional expression profiles across 12 studies, top 6 over- and underexpressed mRNAs were generated. Then, a pair of matched plasma samples from LC patient and normal control was detected by RT-PCR, and three genes with positive bands were selected for further validation. Finally, qPCR was conducted to further assess values of the three identified genes. We displayed with high confidence that two cell-free mRNAs (HJURP and ADAMTS8) were expressed at significantly levels compared to normal controls. Receiver-operating characteristic (ROC) curves on the diagnostic efficacy of plasma HJURP and ADAMTS8 mRNAs in LC diagnosis showed that the area under the ROC (AUC) was 0.6960 and 0.6877; sensitivity was 66.0% and 83.7%; specificity was 78.6% and 71.4%, respectively. Combined ROC analyses using these two biomarkers revealed an elevated AUC of 0.75. Furthermore, the higher HJURP level could be associated with early-stage LC while lower ADAMTS8 level could be correlated with non-small cell lung cancer. Collectively, circulating HJURP and ADAMTS8 mRNAs are promising noninvasive biomarkers for LC diagnosis. Our integrative strategy provides new insights into novel noninvasive biomarker identification for other types of cancer.

show abstract

“…For the use of proper biomarkers in cancer screening procedures, high specificity of at least 95% is required to minimize false positive tests, because they might lead to psychological distress and unnecessary diagnostic interventions or even therapies. However, for subjects formerly exposed to asbestos, there is an increased risk to develop asbestos-associated cancers like lung cancer or mesothelioma [63, 64]. Thus, slightly lower specificity might be tolerable for the use in at-risk collectives.…”

Section: Discussionmentioning

confidence: 99%

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma

et al. 2017

View full text Add to dashboard Cite

The use of circulating microRNAs as biomarkers has opened new opportunities for diagnosis of cancer because microRNAs exhibit tumor-specific expression profiles. The aim of this study was the identification of circulating microRNAs in human plasma as potential biomarkers for the diagnosis of malignant mesothelioma. For discovery, TaqMan Low Density Array Human MicroRNA Cards were used to analyze 377 microRNAs in plasma samples from 21 mesothelioma patients and 21 asbestos-exposed controls. For verification, individual TaqMan microRNA assays were used for quantitative real-time PCR in plasma samples from 22 mesothelioma patients and 44 asbestos-exposed controls. The circulating miR-132-3p showed different expression levels between mesothelioma patients and asbestos-exposed controls. For discrimination, sensitivity of 86% and specificity of 61% were calculated. Circulating miR-132-3p in plasma was not affected by hemolysis and no impact of age or smoking status on miR-132-3p levels could be observed. For the combination of miR-132-3p with the previously described miR-126, sensitivity of 77% and specificity of 86% were calculated. The results of this study indicate that miR-132-3p might be a new promising diagnostic biomarker for malignant mesothelioma. It is indicated that the combination of miR-132-3p with other individual biomarkers improves the biomarker performance.

show abstract

Predictors of lung cancer among former asbestos-exposed workers

Cited by 18 publications

References 17 publications

Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis

Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis

Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma

Contact Info

Product

Resources

About